Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3b, multicenter, randomized, open-label study to evaluate the efficacy and safety of risankizumab compared to vedolizumab in adult patients with moderate to severe ulcerative colitis who have not previously been treated with targeted therapies. This study aims to provide insights into the comparative effectiveness of these two approved treatments, potentially influencing future therapeutic strategies for ulcerative colitis.
The study involves two active comparator groups: one receiving risankizumab and the other vedolizumab. Risankizumab is administered intravenously during the induction phase and subcutaneously during the maintenance phase, while vedolizumab is administered intravenously throughout. Both drugs are intended to reduce inflammation and manage symptoms in ulcerative colitis patients.
This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as the primary purpose. Approximately 530 participants will be enrolled globally, with a study duration of 69 to 71 weeks depending on the treatment group.
The study began on June 17, 2025, with the last update submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and potential impact on AbbVie’s pipeline and market position.
As AbbVie continues to explore new treatment avenues, this study could significantly impact its stock performance and investor sentiment, particularly if risankizumab demonstrates superior efficacy or safety. The outcome may also influence competitive dynamics within the ulcerative colitis treatment market.
The study is ongoing, and further details are available on the ClinicalTrials portal.